Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
Open Access
- 8 August 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 4 (8), e237
- https://doi.org/10.1038/bcj.2014.59
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signalingBlood, 2012
- Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapseLeukemia & Lymphoma, 2012
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood, 2011
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia, 2010
- In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsBlood, 2004